ERBB2 and breast cancer: An individual patient data meta-analysis was then undertaken to determine whether FKBPL could be used prognostically or had value in identifying patients most likely to benefit from tamoxifen therapy or who would be likely to benefit from adjuvant chemotherapy, particularly patients with early stage, ER+, LN-, Her2- breast cancer.